According to the company, the centers of development will include oncology – especially immunotherapy studies – pediatrics, neuro-degenerative disorders, as well as rare and orphan diseases.
"Our centers of therapeutic development are areas of specific focus where we have a lot of experience," Synteract CEO Steve Powell told us.
The CRO will continue to support other therapeutic areas where clients have needs, he explained; "However, by more clearly defining our areas of specialization we have an opportunity to make it easier to answer 'Why Synteract?'"
Echoing this sentiment in the press release, chief commercial officer Jack Shannon said that by “more clearly delineating” the company’s attention on “these growing development areas” it will have “a real opportunity” to expand its presence in the mid-market space.
The new position was created in collaboration with its customers and internal teams, according to the company.